Biotricity, Healthcare

Biotricity receives Health Canada clearance for Biotres

Biotricity Inc. (“Biotricityy”) announced its Health Canada approval for expansion into the US$1.56 billion Canadian Cardiology Devices market. Cardiovascular disease imposes a staggering US$21.2 billion annual cost in Canada alone, accounting for 11.6% of the entire Canadian health care cost.  Health Canada’s approval of Biotres, Biotricity’s flagship product, is a critical step in the Company’s quest to address the needs of more than 2.4 million Canadians living with heart disease and related conditions. This milestone achievement underscores Biotricity’s dedication to reshaping healthcare through innovation.

Privacy Settings
We use cookies to enhance your experience while using our website. If you are using our Services via a browser you can restrict, block or remove cookies through your web browser settings. We also use content and scripts from third parties that may use tracking technologies. You can selectively provide your consent below to allow such third party embeds. For complete information about the cookies we use, data we collect and how we process them, please check our Privacy Policy
Youtube
Consent to display content from - Youtube
Vimeo
Consent to display content from - Vimeo
Google Maps
Consent to display content from - Google
Spotify
Consent to display content from - Spotify
Sound Cloud
Consent to display content from - Sound